Panna Sharma, CEO of clinical stage oncology biotech Lantern Pharma, speaks to EPM about how his company’s artificial intelligence platform could help revolutionise drug development and ultimately change the way we treat cancer.
Automation is to play a key role in transforming regulatory processes in life sciences, but is AI being oversold by business process delivery partners? Alan White, CEO of Arriello, warns that focussed application is essential to delivering results.
The rise of artificial intelligence has been popular within the life sciences industry and in particular pharma. Find out why and what it means for the future of drug development.
Dr Niklas Sandler, chief technology officer at Nanoform, explains why the use of nanonisation and artificial intelligence (AI) can help pharmaceutical manufacturers unlock added value for bioavailable nanoparticles.
Martin Smith, chief technology officer of Pall Corporation, explores how data is finally unlocking the door to continuous bioprocessing in medicine manufacture.
From AI to mHealth, Jim Streeter, global vice president life sciences product strategy Oracle Health Sciences give us his pharma predictions for next year.
New technologies are changing the way pharmaceutical supply chains operate. Here, Marc Herlant, Arthur D. Little, discusses how predictive analytics offers pharmaceutical manufacturers new supply chain capabilities.
Neal Singh, COO of software company Icertis discusses how technology, in particular AI is helping to fast track drug discovery within research and development (R&D).
Nick Lynch, consultant at The Pistoia Alliance discusses how technology, including artificial intelligence (AI), can help automate the lab and accelerate outcomes.
